Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$3.21 - $5.06 $160,500 - $252,999
50,000 New
50,000 $187,000
Q1 2022

May 12, 2022

SELL
$5.5 - $9.19 $293,370 - $490,194
-53,340 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$7.67 - $44.59 $409,117 - $2.38 Million
53,340 New
53,340 $477,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $271M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Anson Funds Management LP Portfolio

Follow Anson Funds Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anson Funds Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Anson Funds Management LP with notifications on news.